Company Overview: Moleculin

Industry News

10 Mar

Moleculin to Present at the 29th Annual Roth Capital Conference

HOUSTON, TX–(Marketwired – March 10, 2017) – Moleculin Biotech, Inc., (MBRX) (“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center,...

Read more

9 Feb

Moleculin Announces Pricing of $5 Million Underwritten Public Offering

HOUSTON, TX–(Marketwired – February 09, 2017) – Moleculin Biotech, Inc., (MBRX) (“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center,...

Read more

19 Jan

Moleculin Announces Expanded Scientific Advisory Board

HOUSTON, TX–(Marketwired – January 19, 2017) – Moleculin Biotech, Inc., (MBRX) (“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center,...

Read more

13 Dec

Moleculin Presents Preclinical Data of Novel Inhibitor of Glycolysis at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

HOUSTON, TX–(Marketwired – December 13, 2016) – Moleculin Biotech, Inc., (MBRX)(“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today...

Read more

17 Nov

Moleculin Announces Positive FDA Guidance Regarding Annamycin IND

HOUSTON, TX–(Marketwired – November 17, 2016) – Moleculin Biotech, Inc., (MBRX)(“Moleculin” or the “Company”), a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer...

Read more

26 Oct

Moleculin Announces Advancement of Preclinical Testing for Brain Tumor Drug WP1122

HOUSTON, TX–(Marketwired – October 26, 2016) – Moleculin Biotech, Inc., (MBRX)(“Moleculin” or the “Company”), a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer...

Read more

Page 1 of 3123

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address